IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward. Read more
Investigator Dr. John Heymach says the positive phase 3 data may lead to a potential new treatment option for patients with resectable NSCLC. Read more
During IASLC’s 2023 Hot Topic Meeting on small cell lung cancer, Dr. Trudy Oliver discussed how MYC genes drive the evolution of SCLC subtypes. Read more
From new diagnostic approaches to new evidence on the potential mechanisms of treatment resistance, Dr. Charles M. Rudin looked back on how small cell research has evolved and what needs remain. Read more
US Food and Drug Administration grants Fast Track designation for novel mesothelioma therapy. Read more
In a recent interview, Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura provides an update on efforts to further refine the system. Read more
Adding to the discussion, Drs. David Ball, Daniel Steinfort, and Susan Harden propose alternative approaches for the complex task of improving nodal staging. Read more
The Netherlands Cancer Institute’s Dr. Paul Baas was honored for his significant contributions to lung cancer research during the 2023 European Lung Cancer Congress. Read more
Consensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC. Read more
ILCN Associate Editors Drs. Suresh Senan and Witold Rzyman add clinical perspective to surveillance frequency discussion. Read more